Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 1 1 2020
medline: 1 7 2020
entrez: 1 1 2020
Statut: ppublish

Résumé

Background and Purpose- Oral anticoagulation therapy is standard of care for patients with nonvalvular atrial fibrillation to prevent stroke. This study compared rivaroxaban and warfarin for stroke and all-cause mortality risk reduction in a real-world setting. Methods- This retrospective cohort study (2011-2017) included de-identified patients from the Optum Clinformatics Database who started treatment with rivaroxaban or warfarin within 30 days following initial diagnosis of nonvalvular atrial fibrillation. Before nonvalvular atrial fibrillation diagnosis, patients had 6 months of continuous health plan enrollment and CHA

Identifiants

pubmed: 31888412
doi: 10.1161/STROKEAHA.119.025554
pmc: PMC7004448
doi:

Substances chimiques

Anticoagulants 0
Factor Xa Inhibitors 0
Warfarin 5Q7ZVV76EI
Rivaroxaban 9NDF7JZ4M3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

549-555

Références

N Engl J Med. 2003 Sep 11;349(11):1019-26
pubmed: 12968085
PLoS One. 2014 Feb 10;9(2):e88225
pubmed: 24520356
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132
pubmed: 30703431
J Clin Epidemiol. 2015 Nov;68(11):1292-300
pubmed: 25700940
J Atr Fibrillation. 2016 Feb 29;8(5):1279
pubmed: 27909470
Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S13-S23
pubmed: 27623681
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
J Stroke Cerebrovasc Dis. 2014 Sep;23(8):2054-2059
pubmed: 25113085
Curr Med Res Opin. 2016 Dec;32(12):2047-2053
pubmed: 27633045
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
J Am Heart Assoc. 2017 Oct 28;6(11):
pubmed: 29080863
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
J Am Heart Assoc. 2016 Mar 08;5(3):e002197
pubmed: 26955859
Stroke. 2014 Dec;45(12):3754-832
pubmed: 25355838
Circulation. 2015 Jan 13;131(2):157-64
pubmed: 25359164
Stud Health Technol Inform. 2014;202:115-8
pubmed: 25000029
J Epidemiol. 2017 Jan;27(1):24-29
pubmed: 28135194
Neurology. 1999 Jul 13;53(1):126-31
pubmed: 10408548
J Am Coll Cardiol. 2018 Mar 6;71(9):1048-1049
pubmed: 29495985
Heart Rhythm. 2016 Aug;13(8):1581-8
pubmed: 27033342
Curr Cardiol Rev. 2014 Nov;10(4):297-302
pubmed: 24821657
Lancet Neurol. 2012 Apr;11(4):315-22
pubmed: 22402056
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
JAMA. 2017 Mar 14;317(10):1057-1067
pubmed: 28291892
Neuroepidemiology. 2013;40(4):227-39
pubmed: 23364221
Stroke. 2018 Dec;49(12):2933-2944
pubmed: 30571400
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
AMIA Annu Symp Proc. 2017 Feb 10;2016:799-807
pubmed: 28269876

Auteurs

Mark Alberts (M)

From Hartford HealthCare, CT (M.A.).

Yen-Wen Chen (YW)

Janssen Scientific Affairs, LLC, Titusville, NJ (Y.-W.C., J.H.L., D.M.).

Jennifer H Lin (JH)

Janssen Scientific Affairs, LLC, Titusville, NJ (Y.-W.C., J.H.L., D.M.).

Emily Kogan (E)

Janssen Research & Development, LLC, Raritan, NJ (E.K., K.T.).

Kathryn Twyman (K)

Janssen Research & Development, LLC, Raritan, NJ (E.K., K.T.).
Mount Sinai Hospital, New York (K.T.).

Dejan Milentijevic (D)

Janssen Scientific Affairs, LLC, Titusville, NJ (Y.-W.C., J.H.L., D.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH